Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab-Reference-Cited by-同舟云学术

Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab

Published:2013-06 Issue:6 Volume:24 Page:1526-1533
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Olson E.M.,Abdel-Rasoul M.,Maly J.,Wu C.S.,Lin N.U.,Shapiro C.L.

Funder

National Cancer Institute

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/24/6/1526/435528/mdt036.pdf

Reference28 articles.

1. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31;Perez;J Clin Oncol,2011

2. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer;Perez;J Clin Oncol,2011

3. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial;Gianni;Lancet Oncol,2011

4. Trastuzumab for patients with axillary-node–positive breast cancer: results of the FNCLCC-PACS 04 Trial;Spielmann;J Clin Oncol,2009

5. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;N Eng J Med,2011

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Why does HER2-positive breast cancer metastasize to the brain and what can we do about it?;Critical Reviews in Oncology/Hematology;2024-03

2. Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer;Neuro-Oncology;2024-02-13

3. Neurotoxicity-sparing radiotherapy for brain metastases in breast cancer: a narrative review;Frontiers in Oncology;2024-02-02

4. Long-term Outcome Analysis of Pyrotinib in Patients With HER2-Positive Metastatic Breast Cancer and Brain Metastasis: A Real-World Study;The Oncologist;2023-08-17

5. Neratinib as adjuvant therapy in patients with HER2 positive breast cancer: expert opinion;Future Oncology;2023-08